S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
Log in
NASDAQ:SNGX

Soligenix Stock Forecast, Price & News

$1.55
-0.12 (-7.19 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.51
Now: $1.55
$1.70
50-Day Range
$1.26
MA: $1.81
$2.75
52-Week Range
$1.21
Now: $1.55
$3.54
Volume6.43 million shs
Average Volume5.41 million shs
Market Capitalization$48.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Soligenix logo

MarketRank

Overall MarketRank

1.36 out of 5 stars

Medical Sector

610th out of 1,928 stocks

Pharmaceutical Preparations Industry

305th out of 774 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNGX
CUSIPN/A
Phone609-538-8200
Employees15

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.60 million
Book Value$0.07 per share

Profitability

Net Income$-9,360,000.00
Net Margins-567.04%

Miscellaneous

Market Cap$48.80 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable
$1.55
-0.12 (-7.19 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Soligenix (NASDAQ:SNGX) Frequently Asked Questions

How has Soligenix's stock been impacted by COVID-19 (Coronavirus)?

Soligenix's stock was trading at $2.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SNGX shares have decreased by 39.0% and is now trading at $1.55.
View which stocks have been most impacted by COVID-19
.

Is Soligenix a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Soligenix stock.
View analyst ratings for Soligenix
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Soligenix?

Wall Street analysts have given Soligenix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Soligenix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Soligenix's CEO?

1,428 employees have rated Soligenix CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Soligenix's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Soligenix's next earnings date?

Soligenix is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Soligenix
.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings data on Thursday, November, 12th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.05. The biopharmaceutical company had revenue of $0.61 million for the quarter, compared to analyst estimates of $1.10 million. Soligenix had a negative return on equity of 328.25% and a negative net margin of 567.04%.
View Soligenix's earnings history
.

What price target have analysts set for SNGX?

4 brokerages have issued 1-year price objectives for Soligenix's stock. Their forecasts range from $2.00 to $5.75. On average, they expect Soligenix's stock price to reach $3.94 in the next twelve months. This suggests a possible upside of 154.0% from the stock's current price.
View analysts' price targets for Soligenix
or view Wall Street analyst' top-rated stocks.

Who are some of Soligenix's key competitors?

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

Who are Soligenix's key executives?

Soligenix's management team includes the following people:
  • Dr. Christopher J. Schaber Ph.D., Chairman, CEO & Pres (Age 55, Pay $604.73k)
  • Mr. Jonathan L. Guarino CPA, CGMA, Sr. VP, CFO & Corp. Sec. (Age 49, Pay $242.65k)
  • Dr. Oreola Donini Ph.D., Sr. VP & Chief Scientific Officer (Age 49, Pay $293.94k)
  • Dr. Richard C. Straube M.D., MSc., Sr. VP & Chief Medical Officer (Age 69, Pay $256.08k)
  • Mr. Richard L. Dunning, Exec. Officer (Age 75)

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $1.55.

How big of a company is Soligenix?

Soligenix has a market capitalization of $48.80 million and generates $4.60 million in revenue each year. The biopharmaceutical company earns $-9,360,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Soligenix employs 15 workers across the globe.

What is Soligenix's official website?

The official website for Soligenix is www.soligenix.com.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.